{"title":"腹膜后纤维化发展为纤维化性纵隔炎患者的特征和预后:病例对照研究和系统评价。","authors":"Yishan Ding, Zhiyan Li, Shibo Liu, Mei Li, Yubo Ren, Kai-Feng Xu, Chenghua Luo, Cuiping Pan, Hui Gao","doi":"10.1002/acr2.70065","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Retroperitoneal fibrosis (RPF) complicated by mediastinal fibrosis (MF) is rare but fatal. We aimed to explore the features and indicators of poor prognosis for the population of those affected.</p><p><strong>Methods: </strong>Patients with idiopathic RPF were recruited in Peking University International Hospital. Literature related to RPF with MF was searched from PubMed, Web of Science, and Embase until September 2024. Systematic review and case-control studies were conducted.</p><p><strong>Results: </strong>One patient with RPF and MF from our center and nine cases identified through literature search formed the study group. The remaining 51 patients with RPF who did not have MF were enrolled as the control group. Patients with RPF and MF were more likely to present specific symptoms, including emaciation (30% vs 2%), fever (20% vs 0), pericardial effusion (30% vs 0), pleurisy (20% vs 0) and dyspnea (40% vs 0) (all P < 0.05). Hyperglobulinemia (elevated IgG levels) was also more predominant in the study group, whereas low back pain (20% vs 56.9%, P = 0.043) was less prevalent. Four of 10 patients in the study group died, but none died in the control group. A second case-control study was performed among patients with RPF and MF, with the three patients who died of fibrosis disease as the study group and the surviving six patients as the control group. It was found that pleural effusions (100% versus 16.7%, P = 0.048) and the absence of glucocorticoid treatment were risk factors for death in patients with RPF and MF.</p><p><strong>Conclusion: </strong>RPF with MF has specific clinical features and poor prognosis. Early detection and glucocorticoids-based treatment could improve the outcome.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"7 8","pages":"e70065"},"PeriodicalIF":2.8000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305350/pdf/","citationCount":"0","resultStr":"{\"title\":\"Features and Prognosis of Patients With Retroperitoneal Fibrosis Developing Fibrosing Mediastinitis: Case-Control Study and Systematic Review.\",\"authors\":\"Yishan Ding, Zhiyan Li, Shibo Liu, Mei Li, Yubo Ren, Kai-Feng Xu, Chenghua Luo, Cuiping Pan, Hui Gao\",\"doi\":\"10.1002/acr2.70065\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Retroperitoneal fibrosis (RPF) complicated by mediastinal fibrosis (MF) is rare but fatal. We aimed to explore the features and indicators of poor prognosis for the population of those affected.</p><p><strong>Methods: </strong>Patients with idiopathic RPF were recruited in Peking University International Hospital. Literature related to RPF with MF was searched from PubMed, Web of Science, and Embase until September 2024. Systematic review and case-control studies were conducted.</p><p><strong>Results: </strong>One patient with RPF and MF from our center and nine cases identified through literature search formed the study group. The remaining 51 patients with RPF who did not have MF were enrolled as the control group. Patients with RPF and MF were more likely to present specific symptoms, including emaciation (30% vs 2%), fever (20% vs 0), pericardial effusion (30% vs 0), pleurisy (20% vs 0) and dyspnea (40% vs 0) (all P < 0.05). Hyperglobulinemia (elevated IgG levels) was also more predominant in the study group, whereas low back pain (20% vs 56.9%, P = 0.043) was less prevalent. Four of 10 patients in the study group died, but none died in the control group. A second case-control study was performed among patients with RPF and MF, with the three patients who died of fibrosis disease as the study group and the surviving six patients as the control group. It was found that pleural effusions (100% versus 16.7%, P = 0.048) and the absence of glucocorticoid treatment were risk factors for death in patients with RPF and MF.</p><p><strong>Conclusion: </strong>RPF with MF has specific clinical features and poor prognosis. Early detection and glucocorticoids-based treatment could improve the outcome.</p>\",\"PeriodicalId\":93845,\"journal\":{\"name\":\"ACR open rheumatology\",\"volume\":\"7 8\",\"pages\":\"e70065\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305350/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACR open rheumatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/acr2.70065\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACR open rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/acr2.70065","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:腹膜后纤维化(RPF)合并纵隔纤维化(MF)是一种罕见但致命的疾病。我们的目的是探讨影响人群预后不良的特征和指标。方法:选取北京大学国际医院特发性RPF患者。截至2024年9月,检索了PubMed、Web of Science和Embase中与MF相关的RPF文献。进行了系统评价和病例对照研究。结果:本中心1例RPF合并MF患者和9例文献检索患者组成研究组。其余51例非MF的RPF患者作为对照组。RPF和MF患者更有可能出现特定症状,包括消瘦(30%比2%)、发热(20%比0)、心包积液(30%比0)、胸膜炎(20%比0)和呼吸困难(40%比0)(均P < 0.05)。高球蛋白血症(IgG水平升高)在研究组中也更为突出,而腰痛(20% vs 56.9%, P = 0.043)则不那么普遍。研究组10例患者中有4例死亡,而对照组没有一例死亡。在RPF和MF患者中进行第二项病例对照研究,以3例死于纤维化疾病的患者为研究组,6例存活的患者为对照组。发现胸腔积液(100%对16.7%,P = 0.048)和未接受糖皮质激素治疗是RPF和MF患者死亡的危险因素。结论:RPF合并MF具有特殊的临床特征,预后较差。早期发现和基于糖皮质激素的治疗可以改善结果。
Features and Prognosis of Patients With Retroperitoneal Fibrosis Developing Fibrosing Mediastinitis: Case-Control Study and Systematic Review.
Objective: Retroperitoneal fibrosis (RPF) complicated by mediastinal fibrosis (MF) is rare but fatal. We aimed to explore the features and indicators of poor prognosis for the population of those affected.
Methods: Patients with idiopathic RPF were recruited in Peking University International Hospital. Literature related to RPF with MF was searched from PubMed, Web of Science, and Embase until September 2024. Systematic review and case-control studies were conducted.
Results: One patient with RPF and MF from our center and nine cases identified through literature search formed the study group. The remaining 51 patients with RPF who did not have MF were enrolled as the control group. Patients with RPF and MF were more likely to present specific symptoms, including emaciation (30% vs 2%), fever (20% vs 0), pericardial effusion (30% vs 0), pleurisy (20% vs 0) and dyspnea (40% vs 0) (all P < 0.05). Hyperglobulinemia (elevated IgG levels) was also more predominant in the study group, whereas low back pain (20% vs 56.9%, P = 0.043) was less prevalent. Four of 10 patients in the study group died, but none died in the control group. A second case-control study was performed among patients with RPF and MF, with the three patients who died of fibrosis disease as the study group and the surviving six patients as the control group. It was found that pleural effusions (100% versus 16.7%, P = 0.048) and the absence of glucocorticoid treatment were risk factors for death in patients with RPF and MF.
Conclusion: RPF with MF has specific clinical features and poor prognosis. Early detection and glucocorticoids-based treatment could improve the outcome.